SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 244 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.14 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $353,338 | +41.3% | 12,818 | +54.0% | 0.00% | – |
| Q2 2023 | $250,101 | -16.3% | 8,322 | +0.9% | 0.00% | -100.0% |
| Q1 2023 | $298,878 | +0.3% | 8,251 | -1.1% | 0.00% | 0.0% |
| Q4 2022 | $297,937 | -63.0% | 8,345 | -65.0% | 0.00% | -50.0% |
| Q3 2022 | $806,000 | +534.6% | 23,840 | +438.5% | 0.00% | – |
| Q2 2022 | $127,000 | -8.0% | 4,427 | +4.0% | 0.00% | – |
| Q1 2022 | $138,000 | +7.8% | 4,258 | -3.0% | 0.00% | – |
| Q4 2021 | $128,000 | +19.6% | 4,389 | +9.2% | 0.00% | – |
| Q3 2021 | $107,000 | -17.1% | 4,019 | -3.5% | 0.00% | – |
| Q2 2021 | $129,000 | +24.0% | 4,164 | +4.2% | 0.00% | – |
| Q1 2021 | $104,000 | +173.7% | 3,995 | +169.8% | 0.00% | – |
| Q4 2020 | $38,000 | -56.3% | 1,481 | -64.4% | 0.00% | – |
| Q3 2020 | $87,000 | -8.4% | 4,161 | +3.1% | 0.00% | – |
| Q2 2020 | $95,000 | +50.8% | 4,037 | +15.1% | 0.00% | – |
| Q1 2020 | $63,000 | – | 3,508 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 426,500 | $11,754,340 | 3.96% |
| ASHFORD CAPITAL MANAGEMENT INC | 916,747 | $25,274,715 | 3.72% |
| ARMISTICE CAPITAL, LLC | 5,092,000 | $140,386,440 | 2.15% |
| S&T BANK/PA | 215,578 | $5,943 | 1.15% |
| Aristotle Capital Boston, LLC | 1,187,981 | $32,752,634 | 1.06% |
| RICE HALL JAMES & ASSOCIATES, LLC | 544,468 | $15,010,983 | 0.95% |
| Tributary Capital Management, LLC | 352,429 | $9,716,468 | 0.92% |
| Bridge City Capital, LLC | 65,297 | $1,800,238 | 0.91% |
| Integral Health Asset Management, LLC | 220,000 | $6,065,400 | 0.84% |
| Retirement Planning Co of New England, Inc. | 51,608 | $1,422,833 | 0.79% |